Open label, randomised, parallel-group, multi-centre study to evaluate the safety, tolerability and immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age.

Trial Profile

Open label, randomised, parallel-group, multi-centre study to evaluate the safety, tolerability and immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12 years of age.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs AS03B (Primary) ; Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 09 Nov 2013 Accrual to date is 76% according to United Kingdom Clinical Research Network record. (7464)
    • 07 Oct 2012 Accrual to date is 94% according to United Kingdom Clinical Research Network record.
    • 02 Feb 2011 Actual end date changed from 27 Sep 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov (NCT00980850).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top